Endothelialization of sirolimus-eluting stents with slow and extended drug release in the porcine overstretch model

Journal of Invasive Cardiology

Volumn 20, Issue 12, 2008, Pages 631-634

  Frey, Daniela ^a   Billinger, Michael ^a   Meier, Pascal ^a   Beslac, Olgica ^b   Grossenbacher, Raphael ^a   Häanni, Beat ^c   Hess, Otto M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b Experimental Surgery Institute   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; DRUG ELUTING STENT; DRUG RELEASE; HEALING IMPAIRMENT; NONHUMAN; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS; SWINE; TISSUE REPAIR; VASCULAR ENDOTHELIUM;

ANIMALS; CORONARY RESTENOSIS; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; METALS; SIROLIMUS; STENTS; SWINE; WOUND HEALING;

EID: 57449110939     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-495.
2. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-1706.
3. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
4. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
5. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005;294:819-825.
6. Serruys PW, Sianos G, Abizaid A, et el. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: The Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-260.
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
8. Schuehlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104-111.
9. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-2434.
10. Silber S, Borggrefe M, Böhm M, et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28 984 Patienten. Der Kardiologe 2007;1:84-111.
11. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
12. Billinger M, Buddeberg F, Hubbell JA, et al. Polymer stent coating for prevention of neointimal hyperplasia. J Invasive Cardiol 2006;18:423-426; Discussion 427.
13. Windecker S, Mayer I, De Pasquale G et al. Stent coating with titanium-nitrideoxide for reduction of neointimal hyperplasia. Circulation 2001;104:928-933.
14. Makanya AN, Sparrow MP, Warui CN, et al. Morphological analysis of the postnatally developing marsupial lung: The quokka wallaby. Anat Rec 2001;262:253-265.
15. Van der Giessen WJ, Lincoff M, Schwartz R, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.